Invasive fungal disease prevention in transplant settings
Mundipharma Research Limited supports clinical research in invasive fungal diseases affecting adults undergoing allogeneic blood and marrow transplantation, with a focus on antifungal protection in highly immunocompromised patients.
- Fungal-free survival
- Allogeneic blood and marrow transplantation
- Antifungal prophylaxis
The sponsor’s activity in this area reflects interest in managing serious opportunistic infections in oncology and transplant care.
Chronic pulmonary aspergillosis in adults
The company funds research into chronic pulmonary aspergillosis, addressing adults with limited treatment options and persistent respiratory disease burden.
- Respiratory symptoms
- Computed tomography
- St George’s Respiratory Questionnaire
This area includes evaluation of clinical and radiological response in a complex pulmonary fungal infection.
Paediatric antifungal therapy
Mundipharma Research Limited also supports studies in paediatric patients from birth to under 18 years who require systemic antifungal treatment or prophylaxis for suspected or confirmed infection.
- Pharmacokinetics
- Safety
- Tolerability
These studies extend interest in antifungal medicine into younger age groups with serious infectious risk.
Systemic fungal infections
The sponsor’s trial portfolio covers broader fungal infections requiring systemic treatment, including cases managed in hospital and specialist care environments.
- Invasive fungal infection
- Systemic antifungals
- Adult and paediatric care
Its research landscape is centred on antifungal treatment needs across severe respiratory, transplant-related, and multi-age patient populations.
